Efficacy and safety of intravenous imatinib in COVID-19 ARDS: a randomized, double-blind, placebo-controlled clinical trial

Leila N. Atmowihardjo, Job R. Schippers, Erik Duijvelaar, Imke H. Bartelink, Pierre M. Bet, Noortje E.L. Swart, Nienke van Rein, Keith Purdy, David Cavalla, Andrew McElroy, Sarah Fritchley, Anton Vonk Noordegraaf, Henrik Endeman, Patricia van Velzen, Matty Koopmans, Harm Jan Bogaard, Leo Heunks, Nicole Juffermans, Marcus J. Schultz, Pieter R. TuinmanLieuwe D.J. Bos, Jurjan Aman*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

9 Citations (Scopus)
13 Downloads (Pure)

Fingerprint

Dive into the research topics of 'Efficacy and safety of intravenous imatinib in COVID-19 ARDS: a randomized, double-blind, placebo-controlled clinical trial'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science